The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Jun 30

PMID 26121478

Citations 66

Authors

Jessica E Potts

Laura J Gray

Emer M Brady

Kamlesh Khunti

Melanie J Davies

Danielle H Bodicoat

Affiliations

Soon will be listed here.

Abstract

Aims: To determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.

Methods: Electronic searches were conducted for randomised controlled trials that compared a glucagon-like peptide-1 receptor agonist therapy at a clinically relevant dose with a comparator treatment (other type 2 diabetes treatment or placebo) in adults with type 2 diabetes and a mean body mass index ≥ 25 kg/m2. Pair-wise meta-analyses and mixed treatment comparisons were conducted to examine the difference in weight change at six months between the glucagon-like peptide-1 receptor agonists and each comparator.

Results: In the mixed treatment comparison (27 trials), the glucagon-like peptide-1 receptor agonists were the most successful in terms of weight loss; exenatide 2 mg/week: -1.62 kg (95% CrI: -2.95 kg, -0.30 kg), exenatide 20 μg: -1.37 kg (95% CI: -222 kg, -0.52 kg), liraglutide 1.2 mg: -1.01 kg (95%CrI: -2.41 kg, 0.38 kg) and liraglutide 1.8 mg: -1.51 kg (95% CI: -2.67 kg, -0.37 kg) compared with placebo. There were no differences between the GLP-1 receptor agonists in terms of weight loss.

Conclusions: This review provides evidence that glucagon-like peptide-1 receptor agonist therapies are associated with weight loss in overweight or obese patients with type 2 diabetes with no difference in weight loss seen between the different types of GLP-1 receptor agonists assessed.

Citing Articles

Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.

Raza F, Altaf R, Bashir T, Asghar F, Altaf R, Tousif S Medicine (Baltimore). 2024; 103(44):e40364.

PMID: 39496023 PMC: 11537668. DOI: 10.1097/MD.0000000000040364.

Anti-Hyperglycemic Medication Management in the Perioperative Setting: A Review and Illustrative Case of an Adverse Effect of GLP-1 Receptor Agonist.

Goron A, Connolly C, Valdez-Sinon A, Hesson A, Helou C, Kirschen G J Clin Med. 2024; 13(20).

PMID: 39458209 PMC: 11509032. DOI: 10.3390/jcm13206259.

Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change: GLP-1 Receptor Agonists and Intraocular Pressure Change.

Hallaj S, Halfpenny W, Chuter B, Weinreb R, Baxter S, Cui Q Am J Ophthalmol. 2024; 269:255-265.

PMID: 39237049 PMC: 11634659. DOI: 10.1016/j.ajo.2024.08.030.

Use of Continuous Glucose Monitoring and Glucagon-Like Peptide 1 Receptor Agonist Therapy to Achieve Individualized Treatment Goals in Insulin-Treated People With Type 2 Diabetes: A Case Series and Expert Opinion.

Ehrhardt N, Aroda V, Galindo R, Peters A, Shubrook J Clin Diabetes. 2024; 42(2):341-350.

PMID: 38666194 PMC: 11040021. DOI: 10.2337/cd23-0047.

The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis.

Yugar L, Sedenho-Prado L, da Silva Ferreira I, Silva C, Sposito A, Cercato C Diabetol Metab Syndr. 2024; 16(1):92.

PMID: 38659064 PMC: 11044464. DOI: 10.1186/s13098-024-01337-5.

References

Freeman J . The pathophysiologic role of incretins. J Am Osteopath Assoc. 2007; 107 Suppl:S6-9. View

Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V . Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin. 2009; 25(1):65-75. DOI: 10.1185/03007990802597951. View

DeFronzo R, Triplitt C, Qu Y, Lewis M, Maggs D, Glass L . Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010; 33(5):951-7. PMC: 2858197. DOI: 10.2337/dc09-1521. View

Janssen P, Rotondo A, Mule F, Tack J . Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther. 2012; 37(1):18-36. DOI: 10.1111/apt.12092. View

Hermansen K, Mortensen L . Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007; 30(12):1127-42. DOI: 10.2165/00002018-200730120-00005. View

Buse J, Bergenstal R, Glass L, Heilmann C, Lewis M, Kwan A . Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2010; 154(2):103-12. DOI: 10.7326/0003-4819-154-2-201101180-00300. View

DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A . Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28(5):1092-100. DOI: 10.2337/diacare.28.5.1092. View

Derosa G, Maffioli P, Salvadeo S, Ferrari I, Ragonesi P, Querci F . Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther. 2010; 12(3):233-40. DOI: 10.1089/dia.2009.0141. View

Kibret T, Richer D, Beyene J . Bias in identification of the best treatment in a Bayesian network meta-analysis for binary outcome: a simulation study. Clin Epidemiol. 2014; 6:451-60. PMC: 4259556. DOI: 10.2147/CLEP.S69660. View

10.

Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C . DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011; 96(5):1301-10. DOI: 10.1210/jc.2010-2081. View

11.

Heine R, Van Gaal L, Johns D, Mihm M, Widel M, Brodows R . Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005; 143(8):559-69. DOI: 10.7326/0003-4819-143-8-200510180-00006. View

12.

Yuan G, Song W, Huang Y, Guo X, Gao Y . Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study. Chin Med J (Engl). 2012; 125(15):2677-81. View

13.

Buse J, Rosenstock J, Sesti G, Schmidt W, Montanya E, Brett J . Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374(9683):39-47. DOI: 10.1016/S0140-6736(09)60659-0. View

14.

Esposito K, Mosca C, Brancario C, Chiodini P, Ceriello A, Giugliano D . GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr Med Res Opin. 2011; 27(8):1519-28. DOI: 10.1185/03007995.2011.590127. View

15.

Nauck M, Frid A, Hermansen K, Shah N, Tankova T, Mitha I . Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2008; 32(1):84-90. PMC: 2606836. DOI: 10.2337/dc08-1355. View

16.

Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic N, Antic S . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009; 52(10):2046-55. PMC: 2744824. DOI: 10.1007/s00125-009-1472-y. View

17.

Apovian C, Bergenstal R, Cuddihy R, Qu Y, Lenox S, Lewis M . Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010; 123(5):468.e9-17. DOI: 10.1016/j.amjmed.2009.11.019. View

18.

Bode B, Brett J, Falahati A, Pratley R . Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother. 2011; 9(6):423-33. DOI: 10.1016/j.amjopharm.2011.09.007. View

19.

Drucker D, Buse J, Taylor K, Kendall D, Trautmann M, Zhuang D . Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008; 372(9645):1240-50. DOI: 10.1016/S0140-6736(08)61206-4. View

20.

Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K . Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010; 375(9733):2234-43. DOI: 10.1016/S0140-6736(10)60406-0. View